Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants
Drug continuously improved motor function and survival in babies after 24 months of treatment
Read More
Tag: Evrysdi
Roche scores EU approval for at-home SMA treatment Evrysdi
Therapy indicated for use in SMA patients aged two months and older
Read More
EU regulators to review Evrysdi for SMA
The decision triggers a £15m milestone payment from Roche to PTC Therapeutics
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
